19-13286647-G-C
Position:
Variant summary
Our verdict is Benign. Variant got -17 ACMG points: 1P and 18B. PP2BP4_ModerateBP6_Very_StrongBS1BS2
The NM_001127222.2(CACNA1A):āc.3409C>Gā(p.Pro1137Ala) variant causes a missense change. The variant allele was found at a frequency of 0.000692 in 1,543,218 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (ā ā ).
Frequency
Genomes: š 0.00053 ( 0 hom., cov: 30)
Exomes š: 0.00071 ( 0 hom. )
Consequence
CACNA1A
NM_001127222.2 missense
NM_001127222.2 missense
Scores
1
6
12
Clinical Significance
Conservation
PhyloP100: 5.35
Genes affected
CACNA1A (HGNC:1388): (calcium voltage-gated channel subunit alpha1 A) Voltage-dependent calcium channels mediate the entry of calcium ions into excitable cells, and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, and gene expression. Calcium channels are multisubunit complexes composed of alpha-1, beta, alpha-2/delta, and gamma subunits. The channel activity is directed by the pore-forming alpha-1 subunit, whereas, the others act as auxiliary subunits regulating this activity. The distinctive properties of the calcium channel types are related primarily to the expression of a variety of alpha-1 isoforms, alpha-1A, B, C, D, E, and S. This gene encodes the alpha-1A subunit, which is predominantly expressed in neuronal tissue. Mutations in this gene are associated with 2 neurologic disorders, familial hemiplegic migraine and episodic ataxia 2. This gene also exhibits polymorphic variation due to (CAG)n-repeats. Multiple transcript variants encoding different isoforms have been found for this gene. In one set of transcript variants, the (CAG)n-repeats occur in the 3' UTR, and are not associated with any disease. But in another set of variants, an insertion extends the coding region to include the (CAG)n-repeats which encode a polyglutamine tract. Expansion of the (CAG)n-repeats from the normal 4-18 to 21-33 in the coding region is associated with spinocerebellar ataxia 6. [provided by RefSeq, Jul 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -17 ACMG points.
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), CACNA1A. . Gene score misZ 5.7845 (greater than the threshold 3.09). Trascript score misZ 3.9354 (greater than threshold 3.09). GenCC has associacion of gene with benign paroxysmal torticollis of infancy, developmental and epileptic encephalopathy, 42, undetermined early-onset epileptic encephalopathy, episodic ataxia type 2, familial or sporadic hemiplegic migraine, spinocerebellar ataxia type 6, Lennox-Gastaut syndrome, migraine, familial hemiplegic, 1.
BP4
Computational evidence support a benign effect (MetaRNN=0.07237178).
BP6
Variant 19-13286647-G-C is Benign according to our data. Variant chr19-13286647-G-C is described in ClinVar as [Likely_benign]. Clinvar id is 195471.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr19-13286647-G-C is described in Lovd as [Likely_benign].
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.000533 (81/151930) while in subpopulation NFE AF= 0.001 (68/67896). AF 95% confidence interval is 0.00081. There are 0 homozygotes in gnomad4. There are 38 alleles in male gnomad4 subpopulation. Median coverage is 30. This position pass quality control queck.
BS2
High AC in GnomAd4 at 81 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CACNA1A | NM_001127222.2 | c.3409C>G | p.Pro1137Ala | missense_variant | 20/47 | ENST00000360228.11 | NP_001120694.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CACNA1A | ENST00000360228.11 | c.3409C>G | p.Pro1137Ala | missense_variant | 20/47 | 1 | NM_001127222.2 | ENSP00000353362.5 | ||
CACNA1A | ENST00000638029.1 | c.3421C>G | p.Pro1141Ala | missense_variant | 20/48 | 5 | ENSP00000489829.1 | |||
CACNA1A | ENST00000573710.7 | c.3415C>G | p.Pro1139Ala | missense_variant | 20/47 | 5 | ENSP00000460092.3 | |||
CACNA1A | ENST00000635727.1 | c.3412C>G | p.Pro1138Ala | missense_variant | 20/47 | 5 | ENSP00000490001.1 | |||
CACNA1A | ENST00000637769.1 | c.3412C>G | p.Pro1138Ala | missense_variant | 20/47 | 1 | ENSP00000489778.1 | |||
CACNA1A | ENST00000636012.1 | c.3412C>G | p.Pro1138Ala | missense_variant | 20/46 | 5 | ENSP00000490223.1 | |||
CACNA1A | ENST00000637736.1 | c.3271C>G | p.Pro1091Ala | missense_variant | 19/46 | 5 | ENSP00000489861.1 | |||
CACNA1A | ENST00000636389.1 | c.3412C>G | p.Pro1138Ala | missense_variant | 20/47 | 5 | ENSP00000489992.1 | |||
CACNA1A | ENST00000637432.1 | c.3421C>G | p.Pro1141Ala | missense_variant | 20/48 | 5 | ENSP00000490617.1 | |||
CACNA1A | ENST00000636549.1 | c.3412C>G | p.Pro1138Ala | missense_variant | 20/48 | 5 | ENSP00000490578.1 | |||
CACNA1A | ENST00000637927.1 | c.3415C>G | p.Pro1139Ala | missense_variant | 20/47 | 5 | ENSP00000489715.1 | |||
CACNA1A | ENST00000635895.1 | c.3412C>G | p.Pro1138Ala | missense_variant | 20/47 | 5 | ENSP00000490323.1 | |||
CACNA1A | ENST00000638009.2 | c.3412C>G | p.Pro1138Ala | missense_variant | 20/47 | 1 | ENSP00000489913.1 | |||
CACNA1A | ENST00000637276.1 | c.3412C>G | p.Pro1138Ala | missense_variant | 20/46 | 5 | ENSP00000489777.1 |
Frequencies
GnomAD3 genomes AF: 0.000534 AC: 81AN: 151812Hom.: 0 Cov.: 30
GnomAD3 genomes
AF:
AC:
81
AN:
151812
Hom.:
Cov.:
30
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000427 AC: 82AN: 191990Hom.: 1 AF XY: 0.000342 AC XY: 35AN XY: 102226
GnomAD3 exomes
AF:
AC:
82
AN:
191990
Hom.:
AF XY:
AC XY:
35
AN XY:
102226
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000709 AC: 987AN: 1391288Hom.: 0 Cov.: 35 AF XY: 0.000688 AC XY: 471AN XY: 684574
GnomAD4 exome
AF:
AC:
987
AN:
1391288
Hom.:
Cov.:
35
AF XY:
AC XY:
471
AN XY:
684574
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000533 AC: 81AN: 151930Hom.: 0 Cov.: 30 AF XY: 0.000512 AC XY: 38AN XY: 74276
GnomAD4 genome
AF:
AC:
81
AN:
151930
Hom.:
Cov.:
30
AF XY:
AC XY:
38
AN XY:
74276
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
3
ALSPAC
AF:
AC:
0
ESP6500AA
AF:
AC:
3
ESP6500EA
AF:
AC:
11
ExAC
AF:
AC:
48
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Mar 16, 2017 | - - |
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Mar 20, 2024 | - - |
not provided Benign:2
Benign, criteria provided, single submitter | clinical testing | GeneDx | Jun 30, 2020 | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Aug 01, 2024 | CACNA1A: PP2, BS2 - |
Episodic ataxia type 2;C4310716:Developmental and epileptic encephalopathy, 42 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 19, 2024 | - - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 27, 2024 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
CACNA1A-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 08, 2022 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
.;T;T;.;.;.;.;.;.;T;.;.;.;T;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;D;D;D;D;D;D;.;D;D;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Benign
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Uncertain
D
MutationAssessor
Benign
.;.;.;.;L;.;.;.;.;.;.;.;L;.;.
PrimateAI
Uncertain
T
PROVEAN
Uncertain
.;D;.;.;.;.;.;.;.;.;.;.;.;.;.
REVEL
Benign
Sift
Benign
.;T;.;.;.;.;.;.;.;.;.;.;.;.;.
Sift4G
Benign
T;T;.;.;.;.;.;.;.;.;.;.;.;.;.
Vest4
MVP
MPC
0.081
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at